Eliminating Meningococcal Epidemics From the African Meningitis Belt: The Case for Advanced Prevention and Control...

Area of Science:

• Epidemiology
• Vaccinology
• Public Health

Background:

• Meningococcal serogroup A conjugate vaccine (MenAfriVac) successfully eliminated serogroup A infections across Africa's meningitis belt.
• Despite MenAfriVac's success, serogroups C, W, and X meningococci persist, causing localized epidemics.

Purpose of the Study:

• To describe the current epidemiology of non-serogroup A meningococcal disease in the African meningitis belt.
• To review the development status of affordable multivalent meningococcal conjugate vaccines.
• To identify key questions for the effective deployment of new vaccines.

Main Methods:

• Review of epidemiological data on meningococcal disease outbreaks.
• Assessment of the progress in developing multivalent meningococcal conjugate vaccines.
• Analysis of public health strategies for vaccine implementation.

Main Results:

• Serogroup A meningococcal infections have been largely eliminated in the meningitis belt due to MenAfriVac.
• Serogroups C, W, and X remain significant threats, responsible for ongoing and focal epidemics.
• Development of affordable multivalent vaccines targeting these non-A serogroups is underway.

Conclusions:

• While MenAfriVac has controlled serogroup A, non-A serogroups necessitate continued surveillance and intervention.
• Multivalent meningococcal conjugate vaccines are crucial for preventing future epidemics caused by circulating C, W, and X strains.
• Strategic planning is required to optimize the use of these emerging vaccines for sustained meningococcal disease control.